liraglutide glp 1 First Generic of Once-Daily GLP-1 Injection Approved for Diabetes Compounded Liraglutide | AgelessRx

Eli Lilly and Novo Nordisk have the strongest large-cap pipelines

A SURMOUNT-1 post-hoc analysis of 2,542 women, published in Obesity in 2025, found perimenopausal women on tirzepatide lost 23% of body weight against 3% on placebo, almost identical to the premenopausal result

These actions make GLP-1 agonists like semaglutide GLP-1 and Zepbound effective for weight loss

In 2022, India ranked third on the list of countries with the most adults with obesity

FDA Commissioner Marty Makary stated that the agency was paying close attention to misleading claims "across all media platforms." For consumers, the most important compliance signal to look for in any compounded GLP-1 program is whether the company accurately describes what its medications are and are not

We are here to help you be even more successful